Para-aortic lymph node recurrence in cervical cancer patients

Objective: The primary aim of the study was to analyze incidence and risk factors for para-aortic lymph node recurrence (PALNR) in IA1 to IB2 International Federation of Gynecology and Obstetrics (FIGO) 2009 stage cervical cancer patients who were initially treated with radical hysterectomy and pelvic lymph node dissection. Methods: We conducted a retrospective analysis of stage I cervical cancer patients who had been treated with radical hysterectomy and pelvic lymphadenectomy with or without adjuvant therapy. We identified 242 patients, of whom 58 (24%) were diagnosed with PALNR by imaging studies. Results: The group of patients with PALNR had higher tumor grades (G1: 2 patients (3.4%); G2: 44 (75.9%) and G3: 12 (20.7%) vs G1: 48 (26.1%), G2: 112 (60.9%) and G3: 24 (13.0%); p = 0.001), more advanced age (median; range 54 (29–78) vs 49 (23–76); p = 0.02) and fewer pelvic lymph nodes harvested during primary surgery (median; range 11 (3–27) vs 14 (2–40); p = 0.002) when compared to patients without PALNR. The prognosis of patients with PALNR was significantly worse when compared to patients without PALNR (5-year overall survival of 72% vs 87%, p = 0.01). 5-year overall survival following PALNR was 69%. We found no association between PALNR and tumor stage, tumor size, the presence of pelvic lymph node metastases or the histopathologic type of the tumor. Conclusion: We conclude that cervical cancer patients with high tumor grade, older age, and low number of pelvic lymph nodes harvested during initial surgery are at higher risk of PALNR.

Cervical cancer recurrence; Para-aortic lymph node recurrence; Para-aortic lymph node metastases; Cervical cancer surgery

[1] International Agency for Research on Cancer. World Healthy Organization. Cervix uteri. GLOBOCAN 2020. 2020. Available at: https://gco.iarc.fr/today/fact-sheets-populations (Accessed: 11 May 2020).

[2] Jansen EEL, Zielonke N, Gini A, Anttila A, Segnan N, Vokó Z, et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. European Journal of Cancer. 2020; 127: 207–223.

[3] Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, et al. The European response to the WHO call to eliminate cervical cancer as a public health problem. International Journal of Cancer. 2020; 277–284.

[4] Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, et al. The European Society of Gynaecolog- ical Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Manage- ment of Patients with Cervical Cancer. Virchows Archiv. 2018; 472: 919–936.

[5] Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical cancer, version 3.2019. JNCCN Journal of the National Comprehensive Cancer Network. 2019; 17: 64–84.

[6] Höckel M, Horn LC, Hentschel B, Höckel S, Naumann G. Total mesometrial resection: High resolution nerve-sparing radical hysterectomy based on developmentally defined surgical anatomy. In- ternational Journal of Gynecologic Cancer. 2003; 13: 791–803.

[7] Landoni F, Colombo A, Milani R, Placa F, Zanagnolo V, Mangioni C. Randomized study between radical surgery and radiotherapy for the treatment of stage IB–IIA cervical cancer: 20-year update. Gynecologic Oncology. 2017; 28: e34.

[8] Cibula D, McCluggage WG. Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecologic Oncology. 2019; 152: 202–207.

[9] Cibula D, Abu-Rustum NR. Pelvic lymphadenectomy in cervical cancer–surgical anatomy and proposal for a new classification system. Gynecologic Oncology. 2010; 116: 33–37.

[10] Matsuo K, Shimada M, Saito T, Takehara K, Tokunaga H, Watan- abe Y, et al. Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IB-IIB cervical cancer. Journal of Gynecologic Oncology. 2018; 29: e11.

[11] McComas KN, Torgeson AM, Ager BJ, Hellekson C, Burt LM, Maurer KA, et al. The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system. Gynecologic Oncology. 2020; 156: 85–92.

[12] Zhou J, Ran J, He Z, Quan S, Chen Q, Wu S, et al. Tailoring Pelvic Lymphadenectomy for Patients with Stage IA2, IB1, and IIA1 Uterine Cervical Cancer. Journal of Cancer. 2015; 6: 377– 381.

[13] Togami S, Kamio M, Yanazume S, Yoshinaga M, Douchi T. Can pelvic lymphadenectomy be omitted in stage IA2 to IIB uterine cervical cancer? International Journal of Gynecological Cancer. 2014; 24: 1072–1076.

[14] Nanthamongkolkul K, Hanprasertpong J. Predictive Factors of Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. Oncology Research and Treatment. 2018; 41: 194–198.

[15] Du R, Li L, Ma S, Tan X, Zhong S, Wu M. Lymph nodes metastasis in cervical cancer: Incidences, risk factors, consequences and imaging evaluations. Asia-Pacific Journal of Clinical Oncology. 2018; 14: e380–e385.

[16] Hsu HC, Tai YJ, Chen YL, Chiang YC, Chen CA, Cheng WF. Factors predicting parametrial invasion in patients with early-stage cervical carcinomas. PLoS ONE. 2018; 13: e0204950.

[17] Yoneda, JY, Braganca, JF, Sarian, LO, Borba, PP, Conceição, JCJ, Zeferino, LC. Surgical treatment of microinvasive cervical cancer. International Journal of Gynecological Cancer. 2015; 25: 694–698.

[18] Bogani G, Vinti D, Murgia F, Chiappa V, Leone Roberti Maggiore U, Martinelli F, et al. Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage II- ICp cervical cancer. International Journal of Gynecologic Cancer. 2019; 29: 1355–1360.

[19] Gallotta V, Giudice MT, Conte C, Sarandeses AV, D’Indinosante M, Federico A, et al. Minimally invasive salvage lymphadenectomy in gynecological cancer patients: a single institution series. European Journal of Surgical Oncology. 2018; 44: 1568–1572.

[20] Gallotta V, Federico A, Gaballa K, D’Indinosante M, Conte C, Giu- dice MT, et al. The role of robotic aortic lymphadenectomy in gynecological cancer: surgical and oncological outcome in a single institution experience. Journal of Surgical Oncology. 2019; 119: 355–360.

[21] Takahashi M, Mitsuhashi N, Sakurai H, Hayakawa K, Niibe H. Para-aortic lymph node recurrence in patients with cervical cancer treated with postoperative irradiation to the pelvis. Anticancer Research. 1997; 17: 2265–2268.

[22] Chen CS, Ou YC, Lin H, Wang CJ, Chen HC, Fang FM, et al. Anal- ysis of prognostic factors and clinical outcomes in uterine cervical carcinoma with isolated para-aortic lymph node recurrence. American Journal of Translational Research. 2019; 11: 7492–7502.

[23] Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N, et al. Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecologic Oncology. 2006; 103: 435–438.

[24] Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, et al. Isolated paraaortic lymph node recurrence after definitive irra- diation for cervical carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2001; 51: 442–448.

[25] Huang E, Wang C, Chen H, Fang F, Huang Y, Wang C, et al. Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. International Journal of Radiation Oncology, Bi- ology, Physics. 2008; 72: 834–842.

[26] Monteil J, Maubon A, Leobon S, Roux S, Marin B, Renaudie J, et al. Lymph node assessment with (18)F-FDG-PET and MRI in uterine cervical cancer. Anticancer Research. 2011; 31: 3865–3871.

[27] Grigsby PW, Vest ML, Perez CA. Recurrent carcinoma of the cervix exclusively in the paraaortic nodes following radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 1994; 28: 451–455.

[28] Niibe Y, Nakano T, Ohno T, Suzuki Y, Oka K, Tsujii H. Prognostic significance of c-erbB-2/her2 expression in advanced uterine cervical carcinoma with para-aortic lymph node metastasis treated with radiation therapy. International Journal of Gynecological Cancer. 2004; 13: 849–855.

[29] Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uter- ine cervix. Gynecologic Oncology. 2018; 29: 1–12.